.Merck & Co.'s TIGIT system has actually suffered yet another problem. Months after shuttering a ...
.After a year specified by pipe cuts, the shift of its CEO as well as cutbacks, Exscientia will merg...
.Cullinan Therapeutics was actually blown away good enough with Port BioMed's bispecific immune acti...
.Within this full week's episode of "The Top Line," our team're diving right into Ferocious Biotech'...
.The confetti is still soaring coming from Eli Lilly's gathering commemorating the approval of Alzhe...
.Welcome to this week's Chutes & Ladders, our summary of notable management hirings, shootings an...
.Adhering to a bad presenting for Lykos Therapies' MDMA applicant for trauma at a latest FDA advisor...
.AN2 Rehabs is actually reconsidering its company in feedback to lackluster midphase data, vowing to...
.Merck & Co. is actually paying for $700 thousand beforehand to challenge Amgen in a blood stream...
.Along With Gilead Sciences almost an FDA selection for its own liver ailment drug seladelpar, the p...